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Abstract
Background: The anti-tumour activity of cisplatin is thought to be a result of its capacity to form DNA adducts
which prevent cellular processes such as DNA replication and transcription. These DNA adducts can effectively
induce cancer cell death, however, there are a range of clinical side effects and drug resistance issues associated
with its use. In this study, the biological properties of three novel dinuclear platinum-based compounds
(that contain alkane bridging linkers of eight, ten and twelve carbon atoms in length) were characterised to assess
their potential as anticancer agents.
Methods: The properties of these compounds were determined using a DNA template containing seven tandem
telomeric repeat sequences. A linear amplification reaction was used in combination with capillary electrophoresis
to quantify the sequence specificity of DNA adducts formed by these compounds at base pair resolution. The DNA
cross-linking ability of these compounds was assessed using denaturing agarose gel electrophoresis and
cytotoxicity was determined in HeLa cells using a colorimetric cell viability assay.
Results: The dinuclear compounds were found to preferentially form DNA adducts at guanine bases and they
exhibited different damage intensity profiles at the telomeric repeat sequences compared to that of cisplatin. The
dinuclear compounds were found to exhibit a low level of cytotoxicity relative to cisplatin and their cytotoxicity
increased as the linker length increased. Conversely, the interstrand cross-linking efficiency of the dinuclear
compounds increased as the linker length decreased and the compound with the shortest alkane linker was
six-fold more effective than cisplatin.
Conclusions: Since the bifunctional compounds exhibit variation in sequence specificity of adduct formation and a
greater ability to cross-link DNA relative to cisplatin they warrant further investigation towards the goal of developing
new cancer chemotherapeutic agents.
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Background
Cancer is one of the most common public health threats
of the 21st century. Globally, it is the leading cause of
death in economically developed countries and the sec-
ond leading cause of death in developing countries [1],
with about 14.1 million cancer cases and 8.2 million
cancer-related deaths estimated to have occurred in
2012 [2]. Whilst this statistical overview of cancer is
considerably bleak, there is a vast amount of promising
research being undertaken, with a primary focus on the
development of novel chemotherapy agents for use in
the clinical treatment of cancer.
cis-diamminedichloro-platinum(II) (cisplatin) is an
FDA-approved, platinum-based drug that has been iden-
tified as a significant breakthrough for use in cancer
chemotherapy, particularly in the treatment of testicular,
cervical, ovarian, head, neck and, small and non-small
cell lung cancer [3]. It is a square planar, mononuclear
compound consisting of a central platinum atom, as
shown in Fig. 1 (a). Unfortunately, there are a range of
associated cytotoxic side effects associated with cis-
platin’s clinical use, such as neurotoxicity, nephrotoxicity
and emetogenesis [4, 5]. In an attempt to resolve these
unwanted consequences, a range of novel platinum-
based analogues have been made and tested. There is a
general consensus that DNA is a key biological target of
cisplatin [6–9], whereby the platinum drug binds pre-
dominantly to the N7 position of purine bases (guanine
and adenine) [10], resulting in the formation of mono-
functional and bifunctional DNA adducts. The majority
of DNA adducts occur as a result of cisplatin binding to
adjacent purine bases on the same strand of the DNA
helix, as intrastrand DNA adducts. It is thought that
DNA intrastrand adducts at GG sequences are the sig-
nificant sites of cisplatin’s biological effectiveness and
anti-tumour activity [11, 12]. The 1,2 GG intrastrand ad-
duct is the most common type of DNA adduct formed
by cisplatin and accounts for approximately 60 % of all
DNA adducts; followed by the 1,2 AG intrastrand ad-
duct, 1,3 GG intrastrand adduct and the GG interstrand
adduct, which account for 20, 5 and 2 % of all DNA
adducts, respectively [10].
In eukaryotic cells, telomeres consist of G-rich se-
quences, consisting of tandem repeats of 5′-TTAGGG-3’
[13, 14] and in immortalised cells, such as cancer cells,
the telomeres do not shorten in a normal manner after
cell division has occurred, due to the activity of the
telomerase enzyme maintaining the length of the telo-
meres [15, 16]. Since cisplatin preferentially forms DNA
adducts at consecutive guanines, the telomeres have
been shown to be effective targets for cisplatin binding
[17–19]. Furthermore, the cisplatin-induced DNA ad-
ducts have been shown to effectively cause telomere loss
in HeLa cells [20] and in patients with advanced head
and neck cancer; ultimately resulting in tumour regres-
sion [21] Hence, the ability of a drug to form DNA
adducts at consecutive guanine bases of telomere se-
quences, is a crucial property to consider in the develop-
ment of novel platinum-based anticancer drugs.
Platinum anti-cancer drugs remain one of the most
widely used family of agents in the treatment of human
cancer. Despite their success, clinical efficacy is often
impeded by severe dose-limiting side effects [22–24].
The limited doses that can be administered to patients
also means that tumors can develop resistance [25]. New
drugs continue to be developed to overcome this issue.
In this investigation we have focused primarily on the
DNA sequence specificity and DNA cross-linking ability
of novel platinum complexes, in addition to investigating
their cytotoxicity in HeLa cells. DNA interactions were
determined using an automated DNA sequencer which
is more precise for measuring the location and intensity
of platinum-DNA adduct formation compared to prior




ane-1,10-diyl)bis(isonicotinamide) (1,10 platinum) and
trans-Diamminedichloroplatinum(II)-N,N’-(dodecane-1,12-
diyl)bis(isonicotinamide) (1,12 platinum), have recently
been synthesised [26]. The 1,8 platinum, 1,10 platinum and
1,12 platinum compounds contain alkane bridging linkers
(separating the two platinum moieties) of eight, ten and
twelve carbon atoms in length, respectively, as shown by
their chemical structures in Fig. 1 (d) to (f). The platinum
groups on either end of the alkane linker are derived from
cisplatin’s related trans-configured isomer, trans-Diammi-
nedichloroplatinum(II) (transplatin), shown in Fig. 1 (b).
The novel compounds were designed as dinuclear trans-
oriented platinum complexes derived from isonicotinic acid
and transplatin joined by a variable length linker, to build
upon the DNA binding profile of this distinct class of anti-
cancer agents. It is thought that these will bind in a differ-
ent way to the mononuclear cisplatin, transplatin and
structurally similar picoplatin (without the 2-methyl group),
as shown in Fig. 1. As a case in point, the trinuclear trans-
oriented platinum complex, BBR3464 is up to 1000-fold
more cytotoxic in vitro than cisplatin and is able to over-
come acquired resistance in a panel of human cancer cell
lines [27, 28] as discussed further in [26]. It should also be
pointed out that picoplatin contains a methyl group,
which protects it from attack by biological nucleophiles,
such as cysteine and methionine containing peptides/pro-
teins [29–31], and attains a higher nuclear concentration
compared with both BBR3464 and cisplatin [32], however,
isonicotinic acid was not methylated in this present study.
An assessment of the biological properties of novel
platinum-based drugs is a crucial first step to predict
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their potential for use in the clinical treatment of cancer.
In the long term, it is anticipated that a knowledge of
platinum-based anti-tumour properties will enable the
design and synthesis of a range of platinum-based drugs
with desirable chemotherapeutic properties that surpass
cisplatin’s clinical efficacy.
This article reports the biological properties of the three
novel dinuclear platinum-based compounds, through the
application of various molecular biology-based techniques.
More specifically, this investigation characterises the se-
quence specificity of DNA adducts induced by the novel
dinuclear platinum-based compounds, using a purified
G-rich DNA template containing seven sites of telo-
meric repeat sequences. Additionally, the interstrand
cross-linking efficiency (ICLE) of the dinuclear com-
pounds, using a purified DNA template, and their
Fig. 1 The chemical structures of cisplatin, transplatin, picoplatin and the three novel dinuclear platinum-based compounds used in this study.
Note that (a) cisplatin, (b) transplatin and (c) picoplatin are mononuclear compounds, consisting of a single central platinum atom; whereas the
(d) 1,8 platinum, (e) 1,10 platinum and (f) 1,12 platinum are dinuclear compounds, consisting of two platinum atoms separated by alkane linker
chains containing 8, 10 and 12 carbon atoms, respectively. Note that picoplatin is shown for reference only and was not used in this study
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cytotoxicity in human tissue culture cells, have been
characterised.
There are a range of methods that can be utilised to
determine the sequence specificity of cisplatin and re-
lated analogues, such as the linear amplification reaction
(LAR) (combined with automated DNA sequencing)
[33] and single-strand ligation PCR (sslig-PCR) [34]. The
LAR in particular, is advantageous for detecting bulky
DNA adducts, which involves Taq DNA polymerase ex-
tending from a radioactively- or fluorescently-labelled
oligonucleotide primer until its activity is terminated by a
DNA adduct [35–37]. Thermal cycling allows the adduct-
containing DNA templates to be linearly amplified, form-
ing truncated DNA fragments that are dependent on the
sites of DNA adduct formation. The same labelled primer
and untreated DNA template are used to carry out
dideoxy sequencing reactions, which provide size stan-
dards that enable the precise determination of compound
sequence specificity. Previously, the LAR was routinely
carried out with a radioactive 32P-labelled oligonucleotide
primer and the compound sequence specificity was ana-
lysed from a DNA sequencing gel [38, 39]. However, more
recently cisplatin’s DNA sequence specificity has effect-
ively been assessed by the LAR procedure, through the in-
corporation of a fluorescently-labelled primer, which is
subsequently analysed by capillary electrophoresis with
laser-induced fluorescence (CE-LIF) [40]. Furthermore,
the use of CE-LIF, in place of the conventional gel electro-
phoresis, is a faster method and the data can be quantified
more accurately [41, 42].
Interstrand cross-links formed by cisplatin are less
abundant than the intrastrand adducts, occurring at a
frequency of approximately 6 % [43]. They are the most
toxic type of DNA adduct, that induce strong local dis-
tortions in the double helix and inhibit the separation of
the DNA strands within cells [44]. This hinders normal
DNA metabolic processes such as DNA replication and
transcription and subsequently causes cell cycle arrest
and apoptosis [45, 46]. These DNA damaging effects as-
sociated with cisplatin-induced interstrand cross-links,
are a desirable property in the continued development
of novel platinum-based antitumour drugs. A com-
pound’s ICLE can effectively be determined through the
application of a denaturing agarose gel assay. In particu-
lar, an alkaline-based denaturing agarose gel has com-
monly been employed to assess the interstrand cross-
linking ability of various platinum-based compounds
[47, 48]. The denaturing agarose gel carried out in this
current investigation was adapted from a novel urea-
based denaturing agarose gel assay [49]. This particular
assay has the ability to effectively separate long double-
stranded DNA (dsDNA) templates (ranging from 1 to
23 kb in length) into their single-stranded DNA (ssDNA)
constituents. The dsDNA and ssDNA conformations can
easily be distinguished on the denaturing agarose gel, as
the ssDNA band exhibits a lower apparent molecular
weight than the dsDNA band. This characteristic is par-
ticularly advantageous for characterising the ICLE of cis-
platin and other novel covalent-binding compounds, as
any compound-induced interstrand cross-links will
prevent the DNA from denaturing. This effect can be
observed on the denaturing agarose gel as a visible re-
tention of the dsDNA. Through the application of this
assay to this current investigation, the ICLE of the di-
nuclear platinum-based compounds were assessed,
using a 2364 bp linearised pUC19 plasmid template.
Lastly this investigation reports the cytotoxicity of the
novel dinuclear platinum-based compounds, which were
assessed in the cervical cancer cell line, HeLa. Cervical
cancer is the second largest cause of cancer-related mor-
tality in woman and was responsible for more than
200,000 deaths in 2010, with 46,000 of these deaths oc-
curring in the 15 to 49 age group [50]. It has been
shown that the combination of bevacizumab (a mono-
clonal antibody to vascular endothelial growth factor)
with cisplatin and radiotherapy, is generally a safer form
of cervical cancer treatment, with only 31 % of patients
experiencing adverse side effects [51]. However, im-
provements can still be made to improve the clinical
effectiveness of platinum-based drugs towards cervical
cancer with reduced adverse side effects. It is for this
reason that there is a need for the continued character-
isation of novel platinum-based compound cytotoxicity
and their associated intracellular effects within cervical
cancer cells. The tetrazolium (MTT) and sulforhoda-
mine B colourimetric assays are commonly utilised to
assess the cytotoxicity of novel platinum-based com-
pounds. More recently, the MTT assay was employed to
determine the cytotoxicity of a novel bifunctional dinu-
clear platinum-based compound in a human ovarian car-
cinoma cell line, whereby it was determined that the two
monofunctional ends of the dinuclear compound were
converted to bifunctional cross-links at a slower rate
than cisplatin [52], contributing to its reduced cytotox-
icity. The MTT assay was similarly employed in this
study, in order to determine the cytotoxicity (IC50) of
the novel dinuclear compounds in HeLa cells. Whilst
the sulforhodamine B assay has been reported to be
more sensitive than the MTT assay, both assays have
been shown to produce comparable results to determine
IC50 values [53]. The broad goal of such in vitro and cell
based experimental approaches is to be able to screen
new compounds quickly and efficiently as a pipeline to
assess their potential use in further clinical trials and to
assess their possible risks. One of the problems of drug
development is the relatively slow transition of new cis-
platin analogues to the clinic and hence the need for fur-
ther studies such as this, that aim to apply modern
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molecular approaches to assess the potential of novel
analogues for therapeutic use in humans.
Methods
Chemicals and starting materials
Cisplatin and transplatin were purchased from Sigma-
Aldrich. The novel dinuclear platinum-based compounds,
1,8 platinum, 1,10 platinum and 1,12 platinum, were de-
signed by Nial Wheate of the University of Sydney,
Australia and synthesised as described in [26]. Cisplatin
and transplatin were dissolved in dimethylformamide
(DMF) to give working stock solutions of 5 mM. The di-
nuclear compounds were dissolved in DMF to give a
working stock solution of 1 mM, as these compounds
were poorly soluble at higher concentrations. For the cyto-
toxicity experiments, the dinuclear compounds were dis-
solved at a concentration of 1 mM in DNase-free water to
resolve complications associated with DMF-induced cyto-
toxicity in cells treated at high drug concentrations.
DH5α E. coli cells transfected with pUC19 containing
an insert of seven telomeric repeat sequences (pUC19/
T7), inserted between the BamHI and HindIII restriction
enzyme sites [40]. This clone pUC19/T7 plasmid was
used for all DNA-drug interactions in this study.
The 5′ FAM-labelled reverse sequencing primer (FAM-
REV) [40] used in the linear amplification procedure, was
purchased HPLC purified from Invitrogen at a 50 nmole
scale, consisting of a 5′–3′ sequence of AACAGCTATG
ACCATG (16 bases long).
The denaturing agarose buffer used in the interstrand cross-
linking procedure, consisted of 0.5 mg/mL bromophenol blue,
8 M urea, 1 % (v/v) tergitol nonyl phenoxypolyethoxylethanol
type-40 and 1 mM tris(hydroxymethyl)aminomethane (Tris)
(pH 8) in DNase-free water. An Amresco 1 kb DNA ladder
(without loading dye) was prepared by adding 9 μL of
denaturing loading buffer to 0.5 μL of the 1 kb ladder,
followed by 0.5 μL of DNase-free water. The denaturing
agarose gel was prepared as a 1.2 % (w/v) agarose gel
containing 1 M urea. The 1 X TAE denaturing gel running
buffer consisted of 40 mM Tris-acetate, 1 mM ethylenedi-
aminetetraacetic acid (EDTA) and 1 M urea (pH 8).
DNA preparation
The pUC19/T7 clone DNA was extracted and purified
from the DH5α E. coli cells, using a Qiagen Plasmid
Maxi purification kit. The purified plasmid pUC19/T7
clone was linearised with a PvuII restriction enzyme
prior to the DNA damage experiments. Following the re-
striction digest, the DNA was concentrated via ethanol
precipitation and the resulting DNA pellet was resus-
pended in an appropriate volume of 10 mM Tris-HCl
(pH 8.8), 0.1 mM Na2EDTA to give a DNA stock con-
centration of no less than 100 ng/μL.
DNA damage reactions
DNA damage reactions were carried out by treating
800 ng of the PvuII-cleaved pUC19/T7 DNA with
various concentrations of each compound. The sam-
ples were prepared in a final reaction volume of
40 μL, consisting of 2 mMN-2-hydroxyethylpipera-
zine-N’-2-ethane sulfonic acid (HEPES) (pH 7.8),
10 mM NaCl and 10 μM EDTA, incubated at 37 °C
for 18 h in the dark. A DMF solvent control was pre-
pared and incubated under the same conditions as
the drug-treated samples by substituting the drug
with 5 % (v/v) DMF. This control was used to assess
any negligible background damage due to potential
solvent effects caused by the DMF-dissolved com-
pounds. After incubation, an ethanol precipitation
was carried out on all samples and the resulting DNA
pellets were re-dissolved in 20 μL of 10 mM Tris-
HCl (pH 8.8), 0.1 mM Na2EDTA.
Linear amplification reaction and dideoxy sequencing
The sites of DNA damage were determined by subject-
ing the drug-treated, PvuII-cleaved pUC19/T7 plasmid
samples to the LAR. In a 20 μL final reaction volume,
48 ng of the drug-treated plasmid DNA was mixed with
1 pmol of the FAM-REV primer, 67 mM Tris-HCl
(pH 8.8), 16.6 mM (NH4)2SO4, 6.7 mM MgCl2, 0.3 mM
dNTPs and 1 U of Taq DNA polymerase [18]. This was
then made up to volume with DNase-free water. The
samples were subjected to 20 cycles of 95 °C for 45 s,
57 °C for 1 min, 72 °C for 45 s, and a final extension of
72 °C for 5 min in a Bio-Rad DNA Engine Dyad Peltier
Thermal Cycler. The reaction products were then etha-
nol precipitated for 1 h on ice to remove artifact DNA
fragments, followed by centrifugation at 20,000 x g for
30 min. The DNA pellets were washed twice with
150 μL of 70 % (v/v) ethanol prior to drying the DNA
pellets and re-suspending in 10 μL of 10 mM Tris-HCl
(pH 8.8), 0.1 mM Na2EDTA. The reaction products
were analysed by submitting a 2 μL aliquot to the
Ramaciotti Centre, University of New South Wales,
Sydney, Australia, where it was analysed on an Applied
Biosystems ABI 3730 Capillary Sequencer. Dideoxy se-
quencing reactions were carried out on the same DNA
template using the same reaction components as the
LAR, but with the addition of 1 mM of ddNTPs
(ddCTP was used in this study to produce its comple-
mentary G sequence trace) and 50 μM of dNTPs. The
dideoxy samples were subjected to the same reaction
conditions and ethanol precipitation procedure as the
LAR samples, and submitted for analysis as described
for the LAR samples above. All LAR experimental re-
sults were consistently reproduced at least three times
for each of the tested compounds.
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Interstrand cross-linking assay
A volume of 25 μL of denaturing agarose gel loading buf-
fer was combined with 5 μL of drug-treated, PvuII-cleaved
pUC19/T7 DNA. Two DMF negative controls were pre-
pared in the same manner, but with the substitution of the
drug-treated DNA with 5 % (v/v) DMF-treated DNA. The
drug-treated samples were heat denatured at 95 °C for
10 min, along with one of the DMF controls (heat dena-
tured ssDNA control). The 1 kb ladder and remaining
DMF control (non-heat denatured dsDNA control) were
placed on ice. The 1.2 % (w/v) denaturing agarose gel was
cast with a Bio-Rad Wide Mini-Sub Cell GT System and
submerged in 1 X TAE/1 M urea buffer (pH 8). The entire
volumes of each of the heat denatured samples and non-
heat denatured sample, were loaded onto the denaturing
agarose gel, along with 10 μL of the 1 kb ladder. Gel elec-
trophoresis was carried out at 4.2 V/cm for 6 h, at 4 °C in
the dark. This allowed the short 340 bp PvuII-cleaved
dsDNA fragments to run off the gel, whilst producing well
resolved bands for the remaining 2364 bp dsDNA frag-
ments (the largest linearised portion of the pUC19 plas-
mid after complete digestion with PvuII). Following
electrophoresis, the gel was washed at least three times
with 1 X TAE buffer (pH 8), followed by staining in 1 X
GelRed stain (diluted in 1 X TAE buffer (pH 8)) for at
least 30 min [49]. The gel was visualised under UV light
with a BioRad Gel Doc 2000 imager and analysed for
compound induced cross-linking, using BioRad Quantity
One gel imaging software to quantify the intensity of
bands on the gel. The interstrand cross-linking assay was
reproduced at least three times for each of the tested
compounds.
Preparation of HeLa cells for cytotoxicity assay
HeLa cells were cultured as sub-confluent monolayers in
75 cm2 culture flasks and maintained at 37 °C in 5 %
CO2 in a Heal Force SMART CELL incubator. The cells
were subcultured twice on a weekly basis in Dulbecco’s
modified eagle medium (DMEM), supplemented with
10 % (v/v) Fetal bovine serum (FBS), 4.5 g/L D-Glucose,
L-Glutamine, 110 mg/L Sodium Pyruvate, 200 U/mL
Penicillin and 200 μg/mL Streptomycin. The HeLa cells
were harvested for cell counting after allowing the cells
to incubate at 37 °C in 5 % CO2 for 3 days, or until the
cells had reached 90 % confluence. The DMEM media
was decanted from the flask and the cells were trypsi-
nised upon the addition of 5 mL of 0.25 % (w/v)
Trypsin-EDTA. Following trypsinisation, 5 mL of fresh
DMEM was added to the flask and this final 10 mL solu-
tion was collected in a Falcon tube, which was then cen-
trifuged at 500 x g for 5 min to pellet the cells. The
media was decanted and the cell pellet was washed with
10 mL of Dulbecco’s phosphate buffered saline (DPBS),
followed by centrifugation at 500 x g for 5 min. The
DPBS was decanted and the cell pellet was resuspended
in 10 mL of fresh DMEM media. A 10 μL aliquot of the
DMEM cell suspension was combined with 10 μL of
0.4 % (w/v) trypan blue solution and the trypan blue/cell
suspension was mixed thoroughly prior to loading a
10 μL aliquot onto a BOECO haemocytometer for cell
counting. The number of cells per mL was calculated
and the 10 mL cell suspension was diluted with DMEM
media to yield a final concentration of 100,000 cells/
mL. This diluted cell suspension was then plated in
100 μL aliquots into the wells of a flat-bottomed 96-
well microtitre plate so that each well of the 96-well
plate contained 10,000 cells. The 96-well plate was
placed into the incubator and maintained at 37 °C with
5 % CO2, for 24 h.
Cytotoxicity assay
The DMEM culture media in the wells of the 96-well plate
were removed by pipette and replaced with 100 μL of fresh
DMEM media containing cisplatin or novel drug analogue
at concentrations of 1, 3, 5, 10, 30, 50 and 100 μM. For the
novel dinuclear compounds, the drug concentration was
extended further to 150, 200 and 300 μM. All drug treat-
ments were carried out in triplicate and untreated cell con-
trols (cells in DMEM without drug) were included for each
experiment. DMF solvent controls (cells in DMEM treated
with no higher than 2 % (v/v) DMF, which corresponds to
the amount of DMF present in cells treated with 100 μM
cisplatin) were also included in triplicate for each experi-
ment. Triplicate water controls, consisting of 70 % DMEM
and 30 % DNase-free water, were included for the dinuclear
compounds, to account for any loss in cell viability induced
by the water present at drug treatments of 300 μM. Empty
wells (containing no cells) were filled with 100 μL DMEM
media, in triplicate, for the DMEM media blank controls.
The 96-well plate was then placed back into the incubator
and maintained at 37 °C with 5 % CO2, for 24 h.
Following drug treatments, the cells were treated with
MTT by adding 50 μL of the MTT-DPBS solution to the
cells in each well of the 96-well plate. Following a 2 h in-
cubation at 37 °C with 5 % CO2, the media was removed
from the wells by pipette and the resulting formazan
crystals were solubilised in 100 μL of DMSO [54]. The
96-well plate was placed on an IKA MTS 2/4 digital
microtitre plate shaker for 30 min to ensure thorough
solubilisation of the formazan crystals prior to measur-
ing the optical density at 550 nm with a Thermo Scien-
tific Multiskan EX microplate reader.
Results
Sequence specificity of the dinuclear platinum-based
compounds in the pUC19/T7 sequence
A modified pUC19/T7 plasmid was utilised for the DNA
sequence specificity assays carried out in this investigation.
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The pUC19/T7 sequence was composed of seven telomeric
repeats consisting of TTAGGG (T1-T7), a site of four con-
secutive guanine bases (G4), two sites of three consecutive
guanine bases (G3I and G3II) and a site of five consecutive
guanine bases (G5), as highlighted in Fig. 2. After treating
separate PvuII-cleaved pUC19/T7 DNA samples with each
compound, the LAR procedure was carried out with the
FAM-REV, which typically yields a 186 bp full length
ssDNA product. The annealing site of the FAM-REV is in-
dicated within the PvuII-cleaved pUC19/T7 sequence in
Fig. 2. The ssDNA products generated by the LAR proced-
ure were analysed on an ABI 3730 capillary sequencer by
fragment analysis, alongside reaction products obtained
from dideoxy sequencing on the untreated PvuII-cleaved
pUC19/T7 DNA.
The LAR experimental conditions were optimised by
treating the DNA template with varying concentrations
of novel dinuclear compound. An optimal compound
concentration of 0.3 μM resulted in both the relatively
even distribution of damage across the entire length of
the DNA template, as shown in Fig. 3 (c) to (g), and the
full length extension product of 186 bp (this corresponds
to the end-point of the ssDNA fragment whereby exten-
sion by Taq DNA polymerase is terminated), as indi-
cated in the G sequence electropherogram in Fig. 3 (a).
DNA damage induced by the compounds can be ob-
served predominantly at the telomeric repeat sequences,
as well as at the other four G-rich sites in the PvuII-
cleaved pUC19/T7 sequence, as shown in Fig. 3 (c) to
(g). For all tested compounds, any solvent effects caused
Fig. 2 Double-stranded sequence of the PvuII-cleaved pUC19/T7 DNA template. The upper strand of the sequence is written in the 5' to 3' direction.
Sites of PvuII restriction enzyme cleavage are indicated by the bold vertical arrows at both ends of the sequence and the annealing site of the REV
primer is shown by a horizontal arrow, with the primer sequence highlighted in green. The seven telomeric repeats sequences (T1 to T7) are
underlined, with the guanines highlighted in red. All other sites of three or more consecutive guanines (G4, G3I, G3II and G5) are highlighted in red
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Fig. 3 Images of LAR electropherograms showing DNA damage induced by cisplatin, transplatin and the novel dinuclear compounds in the PvuII-
cleaved pUC19/T7 sequence. The top two electropherograms represent the (a) G sequence (generated via dideoxy sequencing and used as a reference
for determining the location of all G-rich sites in the sequence) and the (b) 5 % DMF control (without drug). The following five electropherograms show
a trace of peaks corresponding to DNA damage induced by (c) 0.3 μM cisplatin, (d) 0.3 μM transplatin, (e) 0.3 μM 1,8 platinum, (f) 0.3 μM 1,10 platinum
and (g) 0.3 μM 1,12 platinum. For each electropherogram image, the relative fluorescence intensity of the peaks is plotted on the y axis and the relative
DNA fragment size (bp) plotted on the x axis (shown at the top of the G sequence electropherogram). The peak corresponding to the full length
extension product occurs at the expected size of 186 bp in all electropherograms, which is highlighted in the G sequence electropherogram. The primer
annealing site occurs at the left of each electropherogram, as indicated in the 5 % DMF control. The sites of the seven telomeric repeats (T1 to T7) are
indicated, as well as the other G-rich sites (G4, G3I, G3II and G5) at which DNA adducts occur
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by the DMF were found to be negligible compared to
DNA damage caused by the compounds, as evidenced
by the absence of background peaks in the DMF trace
shown in Fig. 3 (b). Compound-induced DNA damage
could not be interpreted at the first two telomeric repeat
sites (T1 and T2) as a result of artifact peaks consistently
present in the DMF controls, which appear to be attrib-
uted to their close proximity to the primer annealing site
[40], as indicated in Fig. 3 (b). The telomeric repeat sites
yielded the highest total percentage of DNA damage
(collective sum of damage induced at T3-T7), attributing
to 16–30 % of total DNA damage within the analysed
pUC19/T7 sequence, thus indicating that they are effect-
ive targets for DNA adduct formation by both the
mononuclear and dinuclear platinum compounds. The
telomeric repeat sites, T5-T7, yielded the most similar
amounts of DNA damage for each compound, with the
level of DNA damage ranging between 3–6 %, as evident
in Fig. 4. Relatively less DNA damage was observed at
the G3I and G3II sites for all compounds, with damage
at these sites not exceeding 3 %; whereas the G5 site
attracted a higher level of damage, ranging from 3–8 %,
as shown in Fig. 4. Interestingly, the 1,8 and 1,10 plat-
inum compounds induced a level of DNA damage at the
G5 site comparable to that induced at the T5-T7 sites,
accounting for over 3 % of DNA damage, as evident in
Fig. 4. However, cisplatin and transplatin induced DNA
damage levels of 7–8 % at the G5 site; approximately
two-fold higher than damage induced by the dinuclear
compounds. Furthermore, it can be noted that cisplatin
and transplatin induced the highest levels of DNA dam-
age at the G4 site, accounting for approximately 8 and
4 % of DNA damage, respectively. In contrast, the dinu-
clear compounds induced low levels of DNA damage at
this same site, accounting for less than 2 % of total DNA
damage.
A subsequent analysis was conducted to further char-
acterise each compounds sequence specificity; paying
particular attention to their damage intensity profiles at
the telomeric repeat sites in the pUC19/T7 sequence.
For each of these sites, the percentage of damage at each
base was determined using GeneMapper software and
normalised to a maximal value of 1, relative to the high-
est percentage of damage. The damage intensities were
averaged from three telomeric repeat sites, T4, T5 and
T6, as these particular telomeric repeats produced the
most consistent damage intensity trends across three re-
peat experiments for each compound tested. Cisplatin
was found to induce the largest intensity of apparent
damage at the third G (G3) in the sequence, followed by
(in decreasing order) the second guanine (G2), first
guanine (G1), the first thymine (T1) and adenine (A), as
shown in Fig. 5 (a). It can be noted that no apparent
damage was induced by cisplatin at the second thymine
(T2) in the sequence. Transplatin displayed a different
damage intensity profile to that of cisplatin, whereby the
most intense apparent damage was induced at G2,
followed by (in decreasing order) G1, G3, A and T1, as
shown in Fig. 5 (b). Interestingly, all three dinuclear
compounds yielded similar damage intensity profiles at
the telomeric repeat sites. The 1,10 platinum and 1,12
platinum compounds produced almost identical damage
intensity profiles, with the highest intensity of apparent
damage being induced at G2, followed by (in decreasing
Fig. 4 Graph highlighting the percentage of DNA damage induced by each compound at the major G-rich sites in the PvuII-cleaved pUC19/T7
sequence. The percentage of overall DNA damage is plotted on the y axis and the nine major G-rich sites plotted on the x axis. The percentage
of DNA damage was determined for each compound at sites in the sequence containing at least three or more consecutive guanine bases. The
total percentage of DNA damage at each G-rich site was calculated from the sum of the percentage of DNA damage at each individual base
within the G-rich site. The error bars represent the SEM, determined from three separate experiments. Note that the T1 and T2 sites have been
omitted as the DNA damage at these sites was unreadable due to artifact peaks present in the DMF control
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order) G1, G3, A, T1 and T2, as evident in Fig. 5 (d) and
(e). The 1,8 platinum compound produced a relatively
similar damage intensity profile to that of 1,10 platinum
and 1,12 platinum, but with a notably higher proportion
of apparent damage being induced at G1, as evident in
Fig. 5 (c). In summary, it can be noted that the unique
damage intensity profiles determined for the novel dinu-
clear compounds, do not match the profile obtained for
cisplatin; rather their damage intensity profile is a close
match to that of transplatin, with the exception being
that apparent damage was detected at the T2 base for
the dinuclear compounds (transplatin did not induce ap-
parent damage at this base).
Interstrand cross-linking efficiency of the dinuclear
platinum-based compounds
The extent of drug-induced DNA cross-linking was de-
termined by measuring the change in ratio of ssDNA to
dsDNA, in each lane of the denaturing agarose gel.
These changes were observed across a drug concentra-
tion gradient ranging from 0.01 to 30 μM. The concen-
tration at which the compounds induced a 50 %
retention of the dsDNA form (i.e. the drug concentra-
tion that prevents 50 % of the dsDNA from being dena-
tured to the ssDNA form on the denaturing agarose gel),
was determined through non-linear regression analysis,
as carried out with GraphPad Prism software. This
measure is a useful indicator of how effectively a novel
drug can cause DNA cross-linking and was analysed
with respect to the reference compound, cisplatin. The
frequency of interstrand cross-linking was calculated ac-
cording to the formula, %ICL/Pt = XL/5408 x rb [55],
whereby %ICL/Pt refers to the percentage of interstrand
cross-links per platinum adduct, XL (XL = -ln A, where
A is the fraction of DNA molecules running as a band
corresponding to the non-cross-linked DNA) is the
number of interstrand cross-links per molecule of the
linearised DNA template and 5408 is the number of nu-
cleotide residues. The rb ratios were estimated from the
molarity of platinum compound and nucleotides present
in the solution at which 50 % of the DNA was resistant
to denaturing. This assumes that all of the drug has
Fig. 5 Graphs illustrating the damage intensity profile induced by
each compound at the telomeric repeat sites in the PvuII-cleaved
pUC19/T7 sequence. The graphs for (a) cisplatin, (b) transplatin, (c) 1,8
platinum, (d) 1,10 platinum and (e) 1,12 platinum, are highlighted in
blue, red, green, purple and orange, respectively. The damage intensity
(normalised to a value of up to 1, whereby a value of 1 was assigned
to the base that yielded the most intense damage) was determined
from the percentage of damage at each base in the telomeric
sequence. The error bars represent the SEM, determined from three
separate telomeric repeat sites – T4, T5 and T6. The six nucleotides of
the telomeric repeat are referred to as T1G1G2G3AT2
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reacted with the DNA. This assumption is supported by
the fact that whilst determining the sequence specificity,
at a 10-fold higher drug concentration, there were still
undamaged DNA sequences present since adding more
platinum compound led to further damage that inter-
fered with the polymerase extension reaction. The ICLE
value for each compound is displayed in Table 1,
whereby the higher the compounds ICLE value, the
greater its DNA cross-linking efficiency.
Two DNA samples treated with only 5 % DMF solvent
were included as negative controls for all experiments,
since DMF was present at this concentration in all
compound-treated DNA samples. For one of these con-
trol samples, the DNA template was denatured into
ssDNA by heating at 95 °C, in keeping with the proced-
ural treatment of the drug-treated samples. The other
control DMF sample was left non-heat denatured to in-
dicate the running position of the dsDNA on the de-
naturing gel. The different running positions of the
dsDNA and ssDNA forms of the 5 % DMF samples, are
evident in the first and third lanes, respectively, of each
denaturing agarose gel image; these are highlighted as
ssDNA and dsDNA in Fig. 6 (a). The extent of cross-
linking of the linear dsDNA template induced by cis-
platin, 1,8 platinum, 1,10 platinum and 1,12 platinum, is
also shown in the lanes to the right of the ssDNA con-
trol in Fig. 6 (a) to (d), respectively. The results obtained
for cisplatin in this investigation, indicate that cisplatin-
treated dsDNA was unable to denature into its ssDNA
form at a drug concentration of 1 μM, as indicated by
the complete absence of the ssDNA band in the de-
naturing agarose gel image in Fig. 6 (a). Furthermore,
the denaturing agarose gels revealed that 50 % of the
dsDNA form was retained at a cisplatin concentration of
0.09 ± 0.01 μM, yielding an ICLE of 6.8 ± 0.5 %, as indi-
cated in Table 1.
An analyses of the results for the three dinuclear
compounds indicate that the most extensive DNA
cross-linking was exhibited by the 1,8 and 1,10 plat-
inum compounds. These two compounds were found
to cause the complete reduction of the ssDNA form at
a lower drug concentration than was observed for cis-
platin, at a drug treatment of 0.3 μM, as highlighted in
the gel images in Fig. 6 (b) and (c). The 1,8 and 1,10
platinum compounds were found to induce a 50 % re-
tention of the dsDNA form at drug concentrations of
0.02 ± 0.01 μM and 0.03 ± 0.01 μM, respectively, as
shown in Table 1. Furthermore, 1,8 platinum yielded an
ICLE of 43.5 ± 19.0 % and 1,10 platinum, an ICLE of 23.1
± 3.9 %. It can be noted that the ICLE values determined
for 1,8 and 1,10 platinum, are approximately 6-fold and 3-
fold higher than cisplatin’s ICLE, respectively. The 1,12
platinum compound induced DNA cross-linking to a
slightly lesser extent than the 1,8 and 1,10 platinum
compounds, causing 50 % of the dsDNA form to be
retained at a drug concentration of 0.06 ± 0.02 μM
and yielding an ICLE of 14.2 ± 6.4 %, as indicated in
Table 1. Out of the three dinuclear compounds, it
can be noted that 1,12 platinum’s interstrand cross-
linking profile is closest to that of cisplatin’s.
It can be noted that the novel dinuclear compounds
caused a complete loss in band intensity, of both the
ssDNA and dsDNA forms, at a low drug concentration
of 1 μM; which was not observed for cisplatin. This ap-
pears to be due to extensive inter-duplex DNA cross-
linking induced by the compounds, whereby these
higher molecular weight DNA structures remained
trapped in the top of the wells of the denaturing agarose
gel. This is evidenced by the band intensities detected in
the top of the gel wells at drug concentrations of 0.3 μM
and 1 μM, as seen in the denaturing agarose gel images
in Fig. 6 (b) to (d).
Cytotoxic activity of the dinuclear platinum-based
compounds in HeLa cells
The degree of cytotoxicity is based on their IC50 values,
as determined from analyses of their dose response
curves. The compound IC50 values were interpolated
from the dose response curves using GraphPad Prism
software. This involved a non-linear regression analysis
Table 1 Summary of the interstrand cross-linking efficiency of the dinuclear platinum compounds experimental values and is
reported along with its corresponding SEM value
Compound ICLE (%) Drug concentration at 50 %
dsDNA retention (μM)




Cisplatin 6.8 ± 0.5 0.09 ± 0.01 1.9E-3 ± 1.4E-4 10.0
1,8 platinum 43.5 ± 19.0 0.02 ± 0.01 4.7E-4 ± 3.1E-4 0.3
1,10 platinum 23.1 ± 3.9 0.03 ± 0.01 5.7E-4 ± 9.6E-5 0.3
1,12 platinum 14.2 ± 6.4 0.06 ± 0.02 1.1E-3 ± 5.0E-4 1.0
The compounds have been arranged vertically in the table alongside their corresponding ICLE values, expressed as a percentage. The drug concentration
(expressed in μM) that induced a 50 % retention of dsDNA, is reported alongside its respective rb value. The amount of nucleotide sample incubated with each
compound was 2 x 10-9 moles, whereby this value was used to calculate the rb value. The ‘last detected data point’ refers to the highest drug concentration
whereby the DNA was still detectable on the agarose gel. All values are reported in the table with their respective SEM values, which were determined from three
separate experiments
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in order to identify the drug concentration that induced
a 50 % inhibition of cell viability. The lead compound,
cisplatin, was utilised as a reference for the comparative
evaluation of novel compound cytotoxicity, with an IC50
value of 9.3 ± 0.2 μM being obtained in this investiga-
tion, as indicated in Table 2. In contrast, the novel dinu-
clear compounds exhibited a relatively weak cytotoxic
activity, with IC50 values of > 40 μM, > 80 μM and >
130 μM for 1,12 platinum, 1,10 platinum and 1,8 plat-
inum, respectively. Interestingly, it can be noted that the
cytotoxic activity of the dinuclear compounds increase
(correlating to a decrease in their IC50 value) with in-
creasing length of their associated alkane linker, with the
IC50 values approximately doubling with an increase in
the alkane linker by two carbons. For instance, the 1,8
platinum compound contains the shortest linker of the
three compounds and produced the highest IC50 value;
almost double the IC50 of 1,10 platinum and almost four
times higher than the IC50 value of 1,12 platinum.
Discussion
Sequence specificity of the dinuclear platinum-based
compounds in the pUC19/T7 sequence
We examined the DNA sequence specificity of three
novel platinum-based dinuclear complexes, consisting
of alkane linker chains of variable lengths, in a DNA
Fig. 6 Images of 1.2 % denaturing agarose gels showing compound-
induced cross-linking of double-stranded, PvuII-cleaved pUC19 DNA.
The denaturing agarose gel images depict bands corresponding to the
large (2364 bp long) PvuII-cleaved pUC19 DNA fragment following
treatment with (a) cisplatin, (b) 1,8 platinum, (c) 1,10 platinum and
(d) 1,12 platinum. The bands corresponding to the non-heat denatured
dsDNA and heat denatured ssDNA forms (of the DMF control samples)
are present on the left and right-hand side of the 1 kb ladder, respectively,
of each gel. In each gel image, the bands to the right of the ssDNA
control, correspond to heat-denatured DNA treated with increasing
concentration of compound, ranging from 0.1 to 100 μM for cisplatin, and
0.01 to 10 μM for the dinuclear compounds (as indicated above each
gel image)
Table 2 Summary of the dinuclear platinum compound-
induced cytotoxicity in HeLa cells
Compound IC50 (μM)




The compounds are ordered vertically in the table alongside their
corresponding IC50 values. These IC50 values represent the drug concentration,
in μM, at which a cell viability of 50 % was obtained, and were determined
from a non-linear regression analysis using GraphPad Prism software. Each IC50
value was determined from the average of three separate experiments
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sequence containing seven tandem telomeric repeats
of TTAGGG and other clusters of G-rich sites, in-
cluding a run of five consecutive guanines, GGGGG.
Cisplatin was utilised as a positive control in this in-
vestigation, as it is known to target telomeric repeats
and other guanine-rich sequences [18, 19, 40]. Transplatin
was similarly used as a positive control for this study, as
the novel dinuclear compounds contain trans-configured
platinum groups at either end of their alkane linker, hence
the sequence specificity of the dinuclear compounds could
be effectively compared and contrasted to that of transpla-
tin. The LAR was carried out, using a fluorescently tagged
primer and CE-LIF, in order to determine the sites of
compound-induced DNA damage (as a result of DNA ad-
ducts formed by the compounds). These data were quanti-
fied at base pair resolution using GeneMapper software.
As expected, the reference compound, cisplatin, was
found to preferentially damage the pUC19/T7 sequence
at guanine bases, particularly at the G-rich telomeric re-
peats (T1 to T7), G4, G5 and with less intense damage
at the G3I and G3II sites. These results are in agreement
with previous cisplatin investigations, which have simi-
larly highlighted that human telomeric repeat sequences
(as well as other G-rich sequences) are strong binding
targets for cisplatin [18, 19, 40, 56]. The sites consisting
of a larger cluster of guanine bases, such as the G5 site,
attracted a higher level of DNA damage than sites with
fewer clusters of guanine bases, such as the G3I site,
which further supports cisplatin’s preference for G-rich
sequences. Furthermore, the high damage intensities de-
tected at the large clusters of consecutive guanine bases
suggest the presence of 1,2 intrastrand GG DNA ad-
ducts, which is cisplatin’s most prevalent form of DNA
adduct [5, 10, 57]. Additionally, cisplatin was found to
cause DNA damage at adenine bases, particularly at the
adenine (A) base following the third guanine base (G3)
in the telomeric repeat sites, which suggests the pres-
ence of 1,2 GA intrastrand DNA adducts; cisplatin’s
second-most common form of DNA adduct [5, 10, 57].
Interestingly, cisplatin induced a higher level of apparent
DNA damage at the first thymine (T1) base of the telo-
meric repeats, rather than at the adenine (A) base, which
is likely attributed to the Taq DNA polymerase pausing
at this site as a result of extensive DNA damage attrib-
uted to DNA adduct formation at the following cluster
of guanine bases (G1, G2 and G3) downstream.
Transplatin was found to exhibit an altered sequence
specificity profile to that of its related isomer, cisplatin.
This was particularly evident upon analysis of their differ-
ing damage intensity profiles at the telomeric repeats. This
difference in sequence specificity between cisplatin and
transplatin, is likely due to the fact that cisplatin forms bi-
functional DNA adducts (through its two chloride leaving
groups), whilst transplatin forms monofunctional DNA
adducts (through one of its chloride leaving groups).
These results are in agreement with a previous sequence
specificity investigation, whereby differing DNA sequence
specificity profiles were similarly determined for cisplatin
and transplatin [58].
The novel dinuclear compounds, 1,8 platinum, 1,10
platinum and 1,12 platinum, were found to exhibit a
unique DNA sequence specificity profile at the telomeric
repeats of the pUC19/T7 sequence. This was evidenced
by the fact that the dinuclear compounds induced a
small amount of DNA damage at the second thymine
(T2) base in the telomeric repeat site, which did not
occur for cisplatin and transplatin. This could be attrib-
uted to the formation of a 1,3 intrastrand adduct be-
tween the third guanine (G3) and second thymine (T2)
of the telomeric site or alternatively, this could be due to
the formation of a 1,2 intrastrand adduct between the
adenine (A) and the second thymine (T2) base. The lat-
ter postulation is in agreement with a recent sequence
specificity study, whereby a range of dinuclear (similar
in structure to the dinuclear compounds in this current
study) and polynuclear platinum-based compounds were
found to exhibit a strong binding affinity for adjacent
adenine and thymine bases [59]. Furthermore, a chem-
ical reactivity assay has previously identified a hypersen-
sitivity of thymine bases to trans-configured dinuclear
platinum compounds in a short oligonucleotide se-
quence, 5′-TGGT-3′, whereby unstacking of the 3′-T
was also detected [60]. It is believed that the dinuclear
platinum compounds atypical sequence specificity at
pyrimidine bases, such as thymine and cytosine, is due
to the length and flexibility of their associated linker
chains, which enables the two platinum moieties to form
long range DNA adducts [61–63]. For instance, it is
likely that one of the platinum moieties on one end of
the dinuclear compound, binds to a guanine base first,
followed by the binding of the other platinum moiety on
the opposite end of the compound. Hence, the first plat-
inum moiety acts as an anchor, which mediates the
binding of the remaining platinum moiety to a base
within a restricted range in the DNA sequence, depend-
ing on the flexibility of the linker chain. It therefore
seems plausible that this mechanism accounts for the
higher proportion of DNA damage induced by the dinu-
clear compounds at thymine bases, as determined in this
current study.
Interstrand cross-linking efficiency of the dinuclear
platinum-based compounds
The ICLE determined for the reference compound, cis-
platin, yielded a value of 6.8 ± 0.5 % in this study. This
value is in agreement with those previously published,
whereby cisplatin’s ICLE has been determined to be ap-
proximately 6 % [43, 52]. The dinuclear platinum-based
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compounds, 1,8 platinum, 1,10 platinum and 1,12 plat-
inum, yielded considerably higher ICLE values than that
of cisplatin, with ICLEs ranging as high as 14 to 44 %.
For instance, the ICLE of 43.5 ± 19.0 % determined for
1,8 platinum in this study, is approximately 6-fold higher
than cisplatin’s ICLE. High interstrand cross-linking effi-
ciencies, attributed to DNA adducts formed by dinuclear
platinum-based compounds containing carbon-based
linkers, are not uncommon and have similarly been re-
ported for novel cis-configured platinum(II) complexes
containing semi-rigid aromatic linkers [64], whereby
they were found to yield high ICLE values ranging from
20 to 40 %. It can be noted that the ICLE values deter-
mined for the dinuclear platinum-based compounds in
this current study, are in the vicinity of the ICLEs re-
ported for the aromatic linker-containing platinum(II)
complexes (mentioned above). Furthermore, high inter-
strand cross-linking efficiencies have similarly been
demonstrated for a range of trans-oriented dinuclear
platinum-based complexes containing variable long-
chain aliphatic linkers [65], whereby ICLE values as high
as 56, 72 and 91 % were determined for dinuclear
platinum-based compounds consisting of 7, 10 and 12
methylene residues, respectively, in their aliphatic linker
chains. It has therefore been proposed that the ICLE of
dinuclear platinum-based compounds, increases in pro-
portion to an increase in length of their aliphatic linker
[65]. Interestingly, the trend observed in this current
study is not in agreement with the conclusions of this
previous study; rather the interstrand cross-linking effi-
ciencies of the dinuclear platinum-based compounds in
this current investigation were found to be inversely pro-
portional to an increase in length of the carbon-based
linker. An explanation for these contrasting results is
that the chemical composition of the linker chain may
also play a role in either facilitating or hindering the
binding efficiency of these dinuclear compounds. For ex-
ample, the dinuclear compounds assessed in this current
study are composed of a carbon-based alkane linker,
whereas the trans-oriented dinuclear compounds, contain-
ing variable long-chain aliphatic linkers (mentioned above),
were synthesised with additional methylene and diethylene-
triamine groups in their linkers. In support of this theory, a
weak ICLE has previously been determined for a dinuclear
platinum-based compound composed of a benzotriazolate
linker [56]. Even though this benzotriazolate-based com-
pound was reported to consist of two platinum moieties at
either end of the linker (similar to the dinuclear com-
pounds analysed in this current study), it was characterised
as having a relatively low ICLE value of approximately 6 %.
This supports the concept that the bulky aromatic ring of
azole, from which the reported linker was composed, hin-
ders its flexibility and attributes to the compounds poor
efficiency to form interstrand cross-links. This indicates
that the length and rigidity of the linker must also be con-
sidered in the design of the dinuclear compounds. However,
it is not possible to predict the activity of a compound
based solely on its structure, since the relationship between
structure and activity is still not fully understood. For in-
stance, this has been demonstrated for mononuclear
platinum-based compounds (similar to cisplatin), whereby
the incorporation of unconventional chemical groups have
been shown to improve their ICLE; producing high ICLE
values above 20 %, upon the incorporation of isopropyla-
mine or azide groups [47, 66].
In general, it was noted that there was an accumula-
tion of DNA sample in the wells of the gel, evident at
dinuclear compound concentrations of 0.3 μM and
above. This is thought to be due to extensive DNA
cross-linking between multiple DNA duplexes, produ-
cing high molecular weight DNA structures that are in-
capable of migrating out of the wells of the gel. Such a
trend has similarly been reported for the novel dinuclear
complex, BBR3535 [55]. In addition to this, a reduction
in DNA band intensity of the ssDNA and dsDNA forms
could also be attributed to a reduction in the intercalat-
ing ability of the GelRed nucleic acid stain due to a high
frequency of DNA adducts, formed by the two platinum
moieties on either end of the compound. This effect has
previously been characterised for ethidium bromide,
whereby its intercalating activity was found to decrease
markedly for DNA pre-damaged with a range of dinu-
clear platinum-based compounds [65]. Overall, the high
ICLE values indicates that these compounds are mark-
edly more effective at inducing a higher frequency of
interstrand DNA cross-links than mononuclear com-
pounds such as cisplatin.
Cytotoxic activity of the dinuclear platinum-based
compounds in HeLa cells
The IC50 value determined for cisplatin in this investiga-
tion was found to be in the order of 9.3 ± 0.2 μM. This
value is in the same vicinity as the IC50 value of 11.4 μM
that was recently determined for cisplatin, which was
similarly assessed in HeLa cells through the application
of the MTT assay [67]. The dinuclear platinum-based
compounds, 1,8 platinum, 1,10 platinum and 1,12 plat-
inum, were found to be relatively less cytotoxic to the
HeLa cells in comparison to cisplatin, as evidenced by
their markedly higher IC50 values. The dinuclear
platinum-based compounds used in this study exhibited
limited solubility in DMF and water, additionally they
tended to precipitate after a 5 day period. Consequently,
fresh stock of these compounds were used for each ex-
periment since their precipitation would reduce the
compounds molarity in solution. Poor aqueous solubility
and stability properties of novel platinum-based com-
pounds, containing bulky ligand groups, are a common
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issue that can interfere with the compounds ability to
exert their cytotoxic activity. For instance, a range of
bulky novel oxaliplatin-derived compounds have been
shown to be less soluble in water than cisplatin as a re-
sult of their long carbon chains [68]. Hence, this indi-
cates that the poor solubility associated with the
dinuclear platinum-based compounds used in this
current study is also due to the long carbon chains.
One promising study has focused on the synthesis of
platinum-based compounds with properties that aim to
circumvent this compound solubility issue, such as
through the substitution of chloride anions with diverse
carboxylate anions, which promotes the aqueous solu-
bility of the compounds and therefore the compound is
available to interact with DNA in solution [69].
An interesting trend that was noted for the dinu-
clear platinum-based compounds in this current
study, was an increase in cytotoxic activity with in-
creasing size of the alkane linker bridging the plat-
inum atoms. As highlighted in the results, the 1,12
platinum compound (containing the longest alkane
linker) was found to be the most cytotoxic of the
three dinuclear compounds, followed by the 1,10 plat-
inum compound (containing the second longest
alkane linker) and the 1,8 platinum compound (con-
taining the shortest alkane linker). This trend has
similarly been reported by a study that analysed the
cytotoxicity of novel dinuclear bifunctional platinum-
based complexes containing aliphatic linker chains of
varying lengths, within two human ovarian carcinoma
cell lines, A2780 (cisplatin-sensitive) and A2780cisR
(cisplatin-resistant) [65]. The results from this previ-
ous investigation indicated that the activity of these
dinuclear compounds increased with growing length
of the aliphatic linker in both cell lines, with the
compound containing the longest linker, exhibiting a
comparable cytotoxicity to that of cisplatin in both
cell lines. Hence, the cytotoxicity trend reported by
this previous study are consistent with the trend re-
ported for the dinuclear platinum-based compounds
in this current investigation; albeit the cytotoxicity of
1,12 platinum was not found to be equivalent to cis-
platin in this study. These findings support the poten-
tial design and synthesis of dinuclear platinum-based
compounds with longer alkane linkers, such as a 1,14
platinum compound, whereby it seems plausible to
assume that such compounds would induce an
equivalent or improved cytotoxicity in comparison to
cisplatin, however, their reduced solubility in water
would likely pose an issue. It may be possible to im-
prove the water solubility of these long-chain linkers
through the incorporation of hydrophilic groups such
as carboxylate groups in the linkers or in the leaving
groups of the platinum complex [69].
Conclusions
The sequence specificity, ICLE and cytotoxic activity of
three novel dinuclear platinum-based complexes, 1,8 plat-
inum, 1,10 platinum and 1,12 platinum, were assessed
through the application of the LAR procedure, denaturing
agarose gel and MTT assay, respectively. The sequence
specificity analysis revealed that the novel dinuclear com-
pounds preferentially damage the DNA at G-rich se-
quences, making the telomeric repeats a promising
candidate for sites of DNA adduct formation in cancer
cells. Furthermore, these compounds were found to ex-
hibit a unique sequence specificity profile, inducing DNA
damage at an additional thymine base at the telomeric re-
peat sites, not detected for cisplatin or transplatin. This al-
tered sequence specificity appears to be attributed to the
flexible alkane linker, which is a key component of the di-
nuclear compounds chemical structure. These compounds
show good potential as anti-cancer agents in regards to
their efficient interstrand cross-linking of DNA, exhibiting
an ICLE of up to 6-fold higher than cisplatin. As inter-
strand DNA adducts are the most cytotoxic form of DNA
adduct, this is a promising anti-tumour property to have.
Despite the dinuclear compounds being capable of form-
ing a high frequency of toxic DNA adducts, they exhibited
a weak cytotoxic activity in the HeLa cells in comparison
to cisplatin. Promisingly, an increase in their cytotoxic ac-
tivity was found to be proportional to an increase in
length of their associated alkane linker, which suggests
that the future design of dinuclear platinum-based
compounds with longer alkane linkers (whilst maintain-
ing good water solubility), may have the potential to
improve their cytotoxicity. The variation in sequence
specificity of these bifunctional analogues in addition to
their greater ability to cross-link DNA relative to cis-
platin, indicates a spectrum of DNA lesions that may
evade DNA repair and may form the basis of new can-
cer chemotherapeutic agents. However it remains to be
seen if these compounds would be effective in a clinical
situation and further cytotoxicity testing and cellular
DNA binding studies, in various cancer cell lines, need
to be carried out as part of the development and assess-
ment of their clinical potential.
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